TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27029851
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of clindamycin by mouth
Study: 27029851
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of azithromycin by mouth
Study: 24285687
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of anthocyanins twice daily for 24 weeks
Study: 22966824
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (scaling, root planing, and oral hygiene instructions)
Study: 17145251
Drug: Long-term therapeutic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapeutic tinzaparin subcutaneously once daily for 3 months
Study: 17145251
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care long-term vitamin-K-antagonist therapy for 3 months
Study: 17145251
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care long-term vitamin-K-antagonist therapy
Study: 14687502
Drug: 250 U/0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 U/0.5 ml/dose of Healive vaccine
Study: 14687502
Drug: 500 U/1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 U/1.0 ml/dose of Healive vaccine
Study: 9013098
Drug: Parenteral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral oestrogen therapy (polyestradiol phosphate 240 mg i.m. every month)
Study: 1327850
Drug: Oral slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow-release theophylline
Study: 27570988
Drug: Intervention arm
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm with pharmacist review of chronic medication according to STOPP‐START criteria; recommendations sent to Primary Care Physician.
Study: 18155216
Drug: 0.4% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% sodium hyaluronate solution
Study: 15991510
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg hyperbaric ropivacaine + 10 microg fentanyl
Study: 28619613
Drug: Supplemental photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental photodynamic therapy (PDT) in one-visit treatment
Study: 28619613
Drug: Supplemental photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental photodynamic therapy (PDT) in two-visit treatment
Study: 28619613
Drug: Chemo-mechanical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-mechanical preparation (CMP) alone in two-visit treatment
Study: 28619613
Drug: Supplemental photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental photodynamic therapy (PDT)
Study: 22933048
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of olanzapine (10 mg)
Study: 22933048
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of olanzapine (10 mg)
Study: 15809124
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GA and EA (CA)
Study: 12136612
Drug: K+ channel
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K+ channel blockers
Study: 12136612
Drug: Traditional anti‐arrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional anti‐arrhythmic drugs
Study: 12136612
Drug: Anti‐arrhythmic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐arrhythmic drug selection
Study: 12136612
Drug: Anti‐arrhythmic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐arrhythmic treatment
Study: 10440638
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg metronidazole administered at 8-hour intervals for 1 week
Study: 10440638
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 8-hour intervals for 1 week
Study: 10440638
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg metronidazole
Study: 7767709
Drug: Periodontal hygienic
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periodontal hygienic treatment (n = 11 after treatment)
Study: 7767709
Drug: Before treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before treatment (n = 9)
Study: 2181860
Drug: 40 mmol
Normalized name: citrate 18 mmol / sodium 140 mmol in L Injection (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mmol Mg aspartate (20 mmol elemental Mg twice daily)
Study: 26366886
Drug: Computer-assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted cognitive behavioral therapy (CBT)
Study: 17182183
Drug: Morphine (15-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (15-90 mg)
Study: 17182183
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine and nortriptyline
Study: 17182183
Drug: Benztropine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benztropine (active placebo, 0.25-1 mg)
Study: 15539665
Drug: Colombian antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colombian antivenom (20 ml initial dose)
Study: 15539665
Drug: Colombian antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colombian antivenom (< 70 ml initial dose)
Study: 11185630
Drug: telmisartan 160
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telmisartan 160 mg
Study: 11185630
Drug: telmisartan 160
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telmisartan 160 mg plus hydrochlorothiazide 25 mg
Study: 9103344
Drug: Generic levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic levothyroxine sodium preparations
Study: 9103344
Drug: All products
Normalized name: All Clear Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: All products (Synthroid, Levoxine, and 2 generic preparations)
Study: 1503098
Drug: Interferon-alpha (IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (IFN alpha) at a dose of 3 megaunits three times a week intramuscularly for 1 year
Study: 6094423
Drug: Ro 09‐0415,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 09‐0415, 1200 mg bd orally before and after challenge with rhinovirus type 9
Study: 25559798
Drug: Linifanib 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linifanib 7.5 mg (arm B)
Study: 25559798
Drug: Linifanib 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linifanib 12.5 mg (arm C)
Study: 10536556
Drug: Org 9487
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 9487 (1.5 mg kg‐1 initial dose followed by three repeat doses or a 30‐min infusion)
Study: 10536556
Drug: Rocuronium (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (two incremental doses)
Study: 10536556
Drug: Neostigmine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine administration after Org 9487
Study: 367024
Drug: Diluted heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted heparin 5 000 IU/ml
Study: 367024
Drug: Concentrated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated heparin 25 000 IU/ml
Study: 31702876
Drug: Trivalent live
Normalized name: influenza vaccine trivalent live 2024-2025 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent live attenuated influenza vaccine (TLAIV)
Study: 19821984
Drug: Internet-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based self-help problem-solving therapy
Study: 15729083
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract (900 mg/day)
Study: 12660503
Drug: Kidney recipients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney recipients receiving oral prednisone (20 patients)
Study: 12660503
Drug: Liver recipients
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver recipients receiving oral prednisone (6 patients)
Study: 580598
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP)
Study: 25266443
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5FU) and leucovorin (LV) as bolus injections (Mayo or modified Mayo) or bi-monthly with bolus and continuous infusion (LV5FU2 or simplified LV5FU2)
Study: 18762597
Drug: Pictogram-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pictogram-based medication instruction sheets
Study: 12115793
Drug: Tumor bed
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor bed radiotherapy (TBRT) using interstitial high-dose-rate brachytherapy (HDR-BT) of 7 x 4.33 Gy (n = 8) and 7 x 5.2 Gy (n = 37)
Study: 9935117
Drug: Culture medium
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture medium with FBS supplemented with physiologic (75 mIU/mL) FSH
Study: 9935117
Drug: Culture medium
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture medium with FBS supplemented with supraphysiologic (7,500 mIU/mL) FSH
Study: 8688926
Drug: Normative Treatment
Normalized name: K Norm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normative Treatment Planning (NTP)
Study: 30997657
Drug: Orafil-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orafil-G
Study: 26039212
Drug: T cell-depleted
Normalized name: tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell-depleted haploidentical transplantation followed by infusion of genetically modified donor T cells (TK007 study)
Study: 26039212
Drug: Sirolimus-based, calcineurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD with unmanipulated PBSCs from haploidentical family donors (TrRaMM study)
Study: 22915288
Drug: LB03002 (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB03002 (sustained-release recombinant human GH)
Study: 19812228
Drug: TNFi+MTX (TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi+MTX (TNF inhibitors combined with Methotrexate)
Study: 14633531
Drug: Preoperative interscalene
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative interscalene block with 30 mL of 0.5% levobupivacaine
Study: 14633531
Drug: Postoperative interscalene
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative interscalene block with 30 mL of 0.5% levobupivacaine
Study: 10975586
Drug: TAK-044 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-044 (25, 50, or 100 mg, i.v.)
Study: 9394260
Drug: Therapy programs
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy programs for depression
Study: 3158620
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied 2% zinc sulfate solution
Study: 24302681
Drug: DHEA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (400 mg)
Study: 23161039
Drug: Scheduled time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled time administration of Ketorolac (bolus after surgical incision and then every 8 hours for 24 hours)
Study: 23161039
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of Ketorolac (2 ml/h for 24 hours)
Study: 20832963
Drug: Ticagrelor (180‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180‐mg loading dose, 90 mg twice daily)
Study: 20832963
Drug: Clopidogrel (300‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300‐ to 600‐mg loading dose, 75 mg/day)
Study: 16015250
Drug: Beverage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage with 5 g beta-glucans from oats
Study: 16015250
Drug: Beverage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage with 10 g beta-glucans from oats
Study: 11796602
Drug: Intranasal NOMV
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal NOMV vaccine
Study: 11796602
Drug: Intranasal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal and oropharyngeal NOMV vaccine
Study: 11796602
Drug: Group receiving
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group receiving extra vaccine dose
Study: 10643695
Drug: Methotrexate treatment
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate treatment with >50% improvement after 1 year
Study: 10643695
Drug: Methotrexate treatment
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate treatment with 20-50% improvement after 1 year
Study: 10643695
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who discontinued methotrexate treatment during the first year
Study: 1380432
Drug: Tropisetron 10mg
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 10mg intravenously before and after cisplatin infusion
Study: 1380432
Drug: Metoclopramide 2
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 2 mg/kg plus lorazepam administered 15 minutes before cisplatin
Study: 6092288
Drug: Antacid 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid 60 ml/day
Study: 30844687
Drug: Selenomethionine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenomethionine (200 μg daily)
Study: 30844687
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (4000 IU daily)
Study: 28911155
Drug: Interleukin‐1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin‐1 receptor antagonist (IL‐1RA)
Study: 23326188
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid alone (66 mg)
Study: 23326188
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (49.5 mg) plus diclofenac sodium (5 mg)
Study: 23326188
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (49.5 mg) plus sodium clodronate (5 mg)
Study: 17614029
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of prednisolone (Pred)
Study: 3087801
Drug: Terfenadine (TRF)
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine (TRF) 60 mg b.i.d. for 7 days
Study: 3087801
Drug: Mequitazine (MQZ)
Normalized name: mequitazine
DrugBank: Mequitazine (DB01071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mequitazine (MQZ) 5 mg b.i.d. for 7 days
Study: 2819021
Drug: Ca-enriched milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-enriched milk (1 pint daily for 4 weeks)
Study: 23458591
Drug: LCI699 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 (0.25 mg twice daily, 1 mg four times daily, and 0.5 mg/1 mg twice daily)
Study: 23458591
Drug: Eplerenone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (50 mg twice daily)
Study: 20579848
Drug: High dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dairy (∼ 1300 mg/d of calcium from dairy products)
Study: 20579848
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium (∼ 1300 mg/d of calcium; ∼ 700 mg/d from diet and 600 mg/d from a supplement)
Study: 16503524
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine intravenous oxytocin infusion)
Study: 15055095
Drug: Modified Hatha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Hatha yoga intervention (1 hour, twice a week for 6 weeks)
Study: 15055095
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment during observation period)
Study: 23681501
Drug: Gadobutrol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadobutrol (all doses)
Study: 20133200
Drug: rFSH only
Normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rFSH only with GnRH antagonist
Study: 18226768
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy plus cardiac resynchronization therapy (CRT)
Study: 18226768
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (OPT)
Study: 16427528
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine IV before surgical incision, followed by normal saline infusion and normal saline IV at wound closure (Group 1)
Study: 16427528
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine IV before surgery, followed by ketamine infusion 600 mug . kg(‐1) . h(‐1) until wound closure (Group 2)
Study: 16427528
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline IV before surgery, followed by saline infusion and then 0.5 mg/kg ketamine IV at wound closure (Group 3)
Study: 8307847
Drug: Propranolol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.2 mg/kg iv)
Study: 8307847
Drug: Atropine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.04 mg/kg iv)
Study: 31100535
Drug: iGlebe (internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlebe (internet-based cognitive behavior therapy) for 5 months
Study: 24907137
Drug: Pediatric aquatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric aquatic therapy
Study: 22887778
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 35% comfrey root extract plus 1.2% methyl nicotinate
Study: 20102347
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.25 mg) injection
Study: 19248200
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg once daily for 8 weeks)
Study: 19248200
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg once daily for 8 weeks)
Study: 19248200
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg once daily for 8 weeks)
Study: 17602058
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens including thalidomide
Study: 17602058
Drug: Bortezomib, thalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib, thalidomide, lenalidomide, and other novel agents
Study: 25595138
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg/day) + inhaled beclometasone (400 μg/day)
Study: 25595138
Drug: Inhaled beclometasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclometasone (400 μg/day)
Study: 25595138
Drug: Atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin + inhaled beclometasone
Study: 21828967
Drug: 2% mupirocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mupirocin ointment applied to the nares twice daily
Study: 21828967
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin plus daily 4% chlorhexidine body washes
Study: 21828967
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin plus daily dilute bleach water baths
Study: 17134636
Drug: n-3 FA
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 FA supplementation (1 to 3.4 g/day) for 4 to 6 months
Study: 15181294
Drug: Fast advancement
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast advancement (30 ml/kg/day)
Study: 15181294
Drug: Slow advancement
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow advancement (15 ml/kg/day)
Study: 7587605
Drug: Hirudo treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudo treatment
Study: 2146242
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g spectinomycin (single intramuscular injection)
Study: 2146242
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg erythromycin base (five-day oral course, three times daily)
Study: 657032
Drug: Topical aerosol
Normalized name: Lidocaine Topical Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aerosol spray containing neomycin sulfate, polymyxin B sulfate and zinc bacitracin
Study: 31915035
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (control group starting at 2 years CA)
Study: 30670238
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (n = 41), 90-minute sessions of physical, cognitive, or social activities twice weekly
Study: 28093370
Drug: G-EO
Normalized name: EO-3021
DrugBank: EO-3021 (DB18358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-EO
Study: 25749543
Drug: Dexamethasone sodium
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone sodium phosphate (DSP) cream applied to the right ear for 15 days